Skip to content

Oocyte vitrification in women at risk of ovarian failure; an observational study with follow-up of children

Oocyte vitrification in women at risk of ovarian failure; an observational study with follow-up of children - Oocyte vitrification

Status
Unknown
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON35039
Enrollment
190
Registered
2010-03-02
Start date
Unknown
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

birth defect congenital malformations

Interventions

None listed

Sponsors

Academisch Medisch Centrum
Lead Sponsor

Eligibility

Age
2 Years to 99 Years

Inclusion criteria

Inclusion criteria: Oocyte vitrification will be offered to women at risk of ovarian failure due to iatrogenic gonadotoxic treatment or due to increasing age, as well as to women undergoing IVF/ICSI in whom unexpectedly no spermatozoa can be obtained at the time of follicle aspiration.;Inclusion criteria;1. Women between the age of 16 and 40 years who are at risk of ovarian failure due to iatrogenic gonadotoxic treatment (cancer treatment);2. Women between the age of 30 and 40 years who are at risk of ovarian failure due to increasing age. ;3. Women between the age of 18 and 42 years undergoing IVF/ICSI during which no spermatozoa can be obtained at the time of follicle aspiration.

Exclusion criteria

Exclusion criteria: 1. Women with borderline or invasive ovarian cancer. 2. Women with contraindications for IVF treatment such as cardiovascular-pulmonary disease, severe diabetes, bleeding disorders, immunodeficiency, morbid obesity, and premature ovarian failure. 3. Women with severe psychopathology, severe anxiety and inability to cope. 4. Women who are, at the time of the requested thawing of their oocytes, above the age at which embryo transfer is considered safe: currently 45 years of age (modelreglement embryowet 2003) 5. Not able or willing to provide informed consent.

Design outcomes

Primary

MeasureTime frame
Primary outcome is the number of congenital abnormalities in babies born after oocyte vitrification (%).

Secondary

MeasureTime frame
Secondary outcomes are the number of oocytes retrieved and vitrified per woman started (%), The number of women returning for thawing of oocytes (%), the live birth rate in women undergoing oocyte vitrification (%), the live birth rate per thaw cycle (%), the number of oocytes surviving the freeze-thaw process (%), the fertilisation rate (%), embryo development, number and type of pregnancy outcome (biochemical-, clinical-, ongoing-, multiple pregnancy rate (%) after freeze-thaw process. Furthermore the live birth rate after natural conception in the same risk group (%), women never becoming pregnant (%), the number of congenital abnormalities after spontaneous attempts (%), the number and type of pregnancy outcome (biochemical-, clinical-, ongoing-, multiple pregnancy rate after spontaneous attempts (%).

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)